​
​

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RARE Stock Forecast

Ultragenyx Pharmaceutical stock forecast is as follows: an average price target of $106.93 (represents a 138.95% upside from RARE’s last price of $44.75) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

RARE Price Target

The average price target for Ultragenyx Pharmaceutical (RARE) is $106.93 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $67.00. This represents a potential 138.95% upside from RARE's last price of $44.75.

RARE Analyst Ratings

Buy

According to 17 Wall Street analysts, Ultragenyx Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for RARE stock is 0 'Strong Buy' (0.00%), 14 'Buy' (82.35%), 2 'Hold' (11.76%), 1 'Sell' (5.88%), and 0 'Strong Sell' (0.00%).

Ultragenyx Pharmaceutical Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Ed ArceH.C. Wainwright$95.00$51.2085.55%112.29%
Nov 06, 2024Joseph SchwartzLeerink Partners$85.00$51.2066.02%89.94%
Jun 06, 2024Salveen RichterGoldman Sachs$67.00$41.4561.64%49.72%
May 31, 2024Dae Gon HaStifel Nicolaus$127.00$38.65228.59%183.80%
May 31, 2024Christopher RaymondRaymond James$135.00$38.65249.29%201.68%
May 31, 2024Joel BeattyRobert W. Baird$72.00$38.6586.29%60.89%
May 31, 2024Whitney IjemCanaccord Genuity$111.00$38.65187.19%148.04%
Apr 15, 2024Dae Gon HaStifel Nicolaus$124.00$42.87189.25%177.09%
Apr 15, 2024Christopher RaymondRaymond James$130.00$42.87203.24%190.50%
Feb 03, 2023-Morgan Stanley$95.00$47.03102.00%112.29%
Row per page
Go to

The latest Ultragenyx Pharmaceutical stock forecast, released on Nov 06, 2024 by Ed Arce from H.C. Wainwright, set a price target of $95.00, which represents a 85.55% increase from the stock price at the time of the forecast ($51.20), and a 112.29% increase from RARE last price ($44.75).

Ultragenyx Pharmaceutical Price Target by Period

1M3M12M
# Anlaysts229
Avg Price Target$90.00$90.00$105.11
Last Closing Price$44.75$44.75$44.75
Upside/Downside101.12%101.12%134.88%

In the current month, the average price target of Ultragenyx Pharmaceutical stock is $90.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 101.12% increase as opposed to Ultragenyx Pharmaceutical's last price of $44.75. This month's average price target is down 0.00% compared to last quarter, and down -14.38% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Wells FargoBuyBuyHold
Oct 01, 2024Cowen & Co.BuyBuyHold
Sep 20, 2024Wells FargoBuyBuyHold
Aug 02, 2024WedbushNeutralNeutralHold
Aug 02, 2024Cantor FitzgeraldOverweightOverweightHold
Jul 22, 2024WedbushBuyBuyHold
Jun 17, 2024Cowen & Co.BuyBuyHold
May 31, 2024BarclaysOverweightOverweightHold
May 31, 2024WedbushBuyBuyHold
May 31, 2024Cantor FitzgeraldOverweightOverweightHold
Row per page
Go to

Ultragenyx Pharmaceutical's last stock rating was published by Wells Fargo on Oct 21, 2024. The company gave RARE a "Buy" rating, the same as its previous rate.

Ultragenyx Pharmaceutical Financial Forecast

Ultragenyx Pharmaceutical Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$98.05M$108.31M$100.50M$103.35M$90.70M$89.34M$79.94M$83.39M$81.65M$86.97M$99.39M$91.54M$81.47M$61.71M$36.31M$35.59M$25.80M
Avg Forecast$182.40M$173.49M$165.98M$163.32M$173.82M$163.01M$156.86M$146.37M$146.62M$135.28M$123.20M$116.03M$119.38M$109.60M$104.81M$104.71M$105.11M$96.46M$87.78M$83.65M$83.80M$81.55M$85.87M$77.04M$70.54M$54.96M$39.34M$36.98M$32.16M$29.16M
High Forecast$196.97M$187.35M$179.24M$176.36M$187.71M$176.03M$169.39M$159.60M$149.75M$135.54M$123.20M$116.03M$124.59M$138.19M$113.18M$113.08M$113.51M$96.46M$87.78M$83.65M$83.80M$81.55M$85.87M$77.04M$70.54M$54.96M$39.34M$36.98M$32.16M$29.16M
Low Forecast$168.87M$160.62M$153.67M$151.20M$160.93M$150.92M$145.23M$134.26M$140.22M$135.03M$123.20M$116.03M$107.11M$95.70M$97.03M$96.95M$97.32M$96.46M$87.78M$83.65M$83.80M$81.55M$85.87M$77.04M$70.54M$54.96M$39.34M$36.98M$32.16M$29.16M
# Analysts64464379137445129955556666945443
Surprise %-------------0.89%1.03%0.96%0.98%0.94%1.02%0.96%1.00%1.00%1.01%1.29%1.30%1.48%1.57%0.98%1.11%0.88%

Ultragenyx Pharmaceutical's average Quarter revenue forecast for Dec 23 based on 5 analysts is $119.38M, with a low forecast of $107.11M, and a high forecast of $124.59M. RARE's average Quarter revenue forecast represents a 21.75% increase compared to the company's last Quarter revenue of $98.05M (Sep 23).

Ultragenyx Pharmaceutical EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137445129955556666945443
EBITDA-------------$-145.10M$-147.96M$-147.51M$-139.25M$-222.69M$-137.14M$-131.76M$-115.10M$-60.92M$-110.33M$-123.98M$-12.61M$-56.86M$37.34M$-107.68M$-87.94M$-110.56M
Avg Forecast$-164.74M$-156.69M$-149.91M$-147.50M$-156.99M$-147.23M$-141.67M$-132.20M$-132.43M$-122.18M$-111.27M$-170.61M$-107.82M$-98.98M$-94.66M$-134.87M$-81.53M$-96.46M$-87.78M$-106.62M$-83.80M$-81.55M$-85.87M$-109.92M$-70.54M$-54.96M$-39.34M$-83.97M$-32.16M$-29.16M
High Forecast$-152.52M$-145.07M$-138.79M$-136.56M$-145.35M$-136.30M$-131.16M$-121.26M$-126.64M$-121.95M$-111.27M$-136.49M$-96.74M$-86.43M$-87.63M$-107.90M$-65.22M$-96.46M$-87.78M$-85.30M$-83.80M$-81.55M$-85.87M$-87.94M$-70.54M$-54.96M$-39.34M$-67.17M$-32.16M$-29.16M
Low Forecast$-177.90M$-169.21M$-161.88M$-159.29M$-169.53M$-158.99M$-152.99M$-144.14M$-135.25M$-122.42M$-111.27M$-204.74M$-112.53M$-124.80M$-102.22M$-161.85M$-97.83M$-96.46M$-87.78M$-127.94M$-83.80M$-81.55M$-85.87M$-131.91M$-70.54M$-54.96M$-39.34M$-100.76M$-32.16M$-29.16M
Surprise %-------------1.47%1.56%1.09%1.71%2.31%1.56%1.24%1.37%0.75%1.28%1.13%0.18%1.03%-0.95%1.28%2.73%3.79%

4 analysts predict RARE's average Quarter EBITDA for Sep 20 to be $-54.96M, with a high of $-54.96M and a low of $-54.96M. This is -247.18% lower than Ultragenyx Pharmaceutical's previous annual EBITDA (Jun 20) of $37.34M.

Ultragenyx Pharmaceutical Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137445129955556666945443
Net Income-------------$-159.65M$-159.83M$-163.97M$-151.83M$-245.11M$-158.16M$-152.32M$-122.46M$-73.00M$-122.43M$-136.14M$-24.01M$-68.84M$25.32M$-119.03M$-93.81M$-112.99M
Avg Forecast-$-13.37M$-17.19M$-27.69M$-111.99M$-119.92M$-122.95M$-129.63M$-128.70M$-141.71M$-158.58M$-184.19M$-163.04M$-198.37M$-199.62M$-145.61M$-86.74M$-156.80M$-151.56M$-115.11M$-118.92M$-120.65M$-114.51M$-120.71M$-100.57M$-111.11M$-137.55M$-92.81M$-137.98M$-143.22M
High Forecast-$-12.08M$-15.53M$-25.02M$-101.19M$-108.36M$-111.09M$-101.04M$-105.48M$-128.04M$-143.29M$-147.36M$-128.46M$-149.26M$-180.37M$-116.49M$-69.39M$-156.80M$-151.56M$-92.08M$-118.92M$-120.65M$-114.51M$-96.57M$-100.57M$-111.11M$-137.55M$-74.25M$-137.98M$-143.22M
Low Forecast-$-14.76M$-18.97M$-30.57M$-123.62M$-132.38M$-135.72M$-150.60M$-173.22M$-156.42M$-175.05M$-221.03M$-242.10M$-260.96M$-220.35M$-174.73M$-104.09M$-156.80M$-151.56M$-138.13M$-118.92M$-120.65M$-114.51M$-144.85M$-100.57M$-111.11M$-137.55M$-111.37M$-137.98M$-143.22M
Surprise %-------------0.80%0.80%1.13%1.75%1.56%1.04%1.32%1.03%0.61%1.07%1.13%0.24%0.62%-0.18%1.28%0.68%0.79%

Ultragenyx Pharmaceutical's average Quarter net income forecast for Sep 20 is $-111.11M, with a range of $-111.11M to $-111.11M. RARE's average Quarter net income forecast represents a -538.92% decrease compared to the company's last Quarter net income of $25.32M (Jun 20).

Ultragenyx Pharmaceutical SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137445129955556666945443
SG&A-------------$74.92M$81.40M$76.65M$72.85M$69.84M$68.14M$67.31M$59.43M$53.88M$53.41M$53.26M$51.04M$42.12M$42.25M$47.52M$41.88M$41.01M
Avg Forecast$158.22M$150.49M$143.98M$141.67M$150.78M$141.41M$136.07M$126.97M$127.19M$117.35M$106.87M$81.40M$103.56M$95.07M$90.91M$64.35M$42.10M$83.67M$76.15M$50.87M$72.69M$70.74M$74.49M$47.22M$61.19M$47.68M$34.13M$32.08M$27.90M$25.29M
High Forecast$170.86M$162.52M$155.48M$152.99M$162.83M$152.70M$146.94M$138.45M$129.90M$117.58M$106.87M$97.68M$108.08M$119.87M$98.18M$77.22M$50.52M$83.67M$76.15M$61.04M$72.69M$70.74M$74.49M$56.67M$61.19M$47.68M$34.13M$32.08M$27.90M$25.29M
Low Forecast$146.49M$139.33M$133.30M$131.16M$139.60M$130.92M$125.98M$116.46M$121.63M$117.13M$106.87M$65.12M$92.91M$83.02M$84.17M$51.48M$33.68M$83.67M$76.15M$40.69M$72.69M$70.74M$74.49M$37.78M$61.19M$47.68M$34.13M$32.08M$27.90M$25.29M
Surprise %-------------0.79%0.90%1.19%1.73%0.83%0.89%1.32%0.82%0.76%0.72%1.13%0.83%0.88%1.24%1.48%1.50%1.62%

Ultragenyx Pharmaceutical's average Quarter SG&A projection for Dec 23 is $103.56M, based on 5 Wall Street analysts, with a range of $92.91M to $108.08M. The forecast indicates a 38.23% rise compared to RARE last annual SG&A of $74.92M (Sep 23).

Ultragenyx Pharmaceutical EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137445129955556666945443
EPS-------------$-2.23$-0.00$-2.33$-2.16$-3.50$-2.26$-2.19$-1.79$-1.08$-1.81$-2.03$-0.37$-1.13$0.42$-2.05$-1.62$-1.96
Avg Forecast-$-0.14$-0.18$-0.29$-1.17$-1.26$-1.29$-1.36$-1.35$-1.48$-1.66$-1.75$-1.71$-2.08$-2.09$-1.99$-2.13$-1.81$-1.75$-1.78$-1.37$-1.39$-1.32$-1.24$-1.16$-1.28$-1.59$-1.62$-1.59$-1.65
High Forecast-$-0.13$-0.16$-0.26$-1.06$-1.13$-1.16$-1.06$-1.10$-1.34$-1.50$-1.58$-1.35$-1.56$-1.89$-1.80$-1.93$-1.81$-1.75$-1.78$-1.37$-1.39$-1.32$-1.24$-1.16$-1.28$-1.59$-1.62$-1.59$-1.65
Low Forecast-$-0.15$-0.20$-0.32$-1.29$-1.39$-1.42$-1.58$-1.81$-1.64$-1.83$-1.93$-2.54$-2.73$-2.31$-2.20$-2.36$-1.81$-1.75$-1.78$-1.37$-1.39$-1.32$-1.24$-1.16$-1.28$-1.59$-1.62$-1.59$-1.65
Surprise %-------------1.07%0.00%1.17%1.01%1.93%1.29%1.23%1.30%0.78%1.37%1.63%0.32%0.88%-0.26%1.27%1.02%1.18%

According to 4 Wall Street analysts, Ultragenyx Pharmaceutical's projected average Quarter EPS for Sep 20 is $-1.28, with a low estimate of $-1.28 and a high estimate of $-1.28. This represents a -405.55% decrease compared to RARE previous annual EPS of $0.42 (Jun 20).

Ultragenyx Pharmaceutical Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.40$3.67817.50%Buy
INZYInozyme Pharma$3.13$14.67368.69%Buy
PDSBPDS Bio$2.01$9.00347.76%Buy
ARVNArvinas$22.48$71.82219.48%Buy
ABOSAcumen Pharmaceuticals$2.40$7.00191.67%Buy
DAWNDay One Biopharmaceuticals$13.31$38.80191.51%Buy
APLSApellis Pharmaceuticals$26.27$74.50183.59%Buy
RAREUltragenyx Pharmaceutical$44.75$106.93138.95%Buy
TERNTerns Pharmaceuticals$6.17$14.25130.96%Buy
KURAKura Oncology$15.92$26.0063.32%Buy
CRNXCrinetics Pharmaceuticals$54.72$70.1428.18%Buy
AMLXAmylyx Pharmaceuticals$4.76$5.3311.97%Buy
INCYIncyte$75.87$84.5611.45%Buy
RVMDRevolution Medicines, Inc. Warrant$55.13$60.639.98%Buy
ALNYAlnylam Pharmaceuticals$235.56$254.217.92%Buy
UTHRUnited Therapeutics$363.25$358.20-1.39%Buy

RARE Forecast FAQ

Is Ultragenyx Pharmaceutical a good buy?

Yes, according to 17 Wall Street analysts, Ultragenyx Pharmaceutical (RARE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 82.35% of RARE's total ratings.

What is RARE's price target?

Ultragenyx Pharmaceutical (RARE) average price target is $106.93 with a range of $67 to $150, implying a 138.95% from its last price of $44.75. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ultragenyx Pharmaceutical stock go up soon?

According to Wall Street analysts' prediction for RARE stock, the company can go up by 138.95% (from the last price of $44.75 to the average price target of $106.93), up by 235.20% based on the highest stock price target, and up by 49.72% based on the lowest stock price target.

Can Ultragenyx Pharmaceutical stock reach $70?

RARE's average twelve months analyst stock price target of $106.93 supports the claim that Ultragenyx Pharmaceutical can reach $70 in the near future.

What is Ultragenyx Pharmaceutical's current price target trend?

2 Wall Street analysts forecast a $90 price target for Ultragenyx Pharmaceutical (RARE) this month, up 101.12% from its last price of $44.75. Compared to the last 3 and 12 months, the average price target increased by 101.12% and increased by 134.88%, respectively.

What are Ultragenyx Pharmaceutical's analysts' financial forecasts?

Ultragenyx Pharmaceutical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $640.07M (high $692.74M, low $591.33M), average EBITDA is $-578M (high $-534M, low $-626M), average net income is $-484M (high $-422M, low $-542M), average SG&A $555.23M (high $600.92M, low $512.96M), and average EPS is $-5.074 (high $-4.416, low $-5.679). RARE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $685.19M (high $739.92M, low $634.36M), average EBITDA is $-619M (high $-573M, low $-668M), average net income is $-58.251M (high $-52.633M, low $-64.301M), average SG&A $594.37M (high $641.85M, low $550.28M), and average EPS is $-0.61 (high $-0.551, low $-0.673).

Did the RARE's actual financial results beat the analysts' financial forecasts?

Based on Ultragenyx Pharmaceutical's last annual report (Dec 2022), the company's revenue was $363.33M, which missed the average analysts forecast of $373.01M by -2.60%. Apple's EBITDA was $-639M, beating the average prediction of $-372M by 71.70%. The company's net income was $-707M, beating the average estimation of $-510M by 38.65%. Apple's SG&A was $278.14M, beating the average forecast of $252.79M by 10.03%. Lastly, the company's EPS was $-10.12, beating the average prediction of $-7.478 by 35.34%. In terms of the last quarterly report (Sep 2023), Ultragenyx Pharmaceutical's revenue was $98.05M, missing the average analysts' forecast of $109.6M by -10.53%. The company's EBITDA was $-145M, beating the average prediction of $-98.983M by 46.59%. Ultragenyx Pharmaceutical's net income was $-160M, missing the average estimation of $-198M by -19.52%. The company's SG&A was $74.92M, missing the average forecast of $95.07M by -21.20%. Lastly, the company's EPS was $-2.23, beating the average prediction of $-2.077 by 7.35%